PT  - JOURNAL ARTICLE
AU  - LEONARD CHRISTOPHER SCHMEEL
AU  - FREDERIC CARSTEN SCHMEEL
AU  - INGO G.H. SCHMIDT-WOLF
TI  - Clofibrate Demonstrates Efficacy in <em>In Vitro</em> Treatment of Lymphoma and Multiple Myeloma
DP  - 2016 Jul 01
TA  - Anticancer Research
PG  - 3395--3400
VI  - 36
IP  - 7
4099  - http://ar.iiarjournals.org/content/36/7/3395.short
4100  - http://ar.iiarjournals.org/content/36/7/3395.full
SO  - Anticancer Res2016 Jul 01; 36
AB  - Background/Aim: Multiple myeloma (MM), a hematological malignancy of monoclonal B-lymphocytes, remains largely incurable and novel treatments are urgently required. Aberrant activation of wingless-related integration site (WNT)/β-catenin signaling has been demonstrated in both lymphoma and MM, rendering its signaling molecules attractive for the development of new targeted-therapies. Clofibrate has proven anticarcinogenic effects attributed to peroxisome proliferator-activated receptor alpha (PPARα) agonism, also affecting WNT-associated signaling molecules. Materials and Methods: The antitumor apoptotic effect of clofibrate at doses ranging from 0.1-600 μM was investigated on four human and one murine myeloma cell lines, as well as in two human lymphoma cell lines, using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-bromide assay. Results: Clofibrate significantly reduced cell viability in all tested myeloma and lymphoma cell lines in a dose-dependent manner, while healthy cells were hardly affected. Conclusion: Given the known safety profile and induction of apoptosis at low effective doses, our data warrant further investigation of clofibrate as a novel therapy agent in MM.